CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

Sponsor
Navy General Hospital, Beijing
Study ID
NCT06470841
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CHG Combined With Venetoclax and Azacytidine — DRUG
    Patients were treated by CHG Combined With Venetoclax and Azacytidine: Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14.

Study Details

The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.

Key Dates

Start date
Sep 20, 2024
Status verified
Aug 2024
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
85 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CHG Combined With Venetoclax and Azacytidine
    Patients were treated by CHG Combined With Venetoclax and Azacytidine

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: 1 year ]

Central Contacts

Related Studies